ENTITY
SMARTSCORE: 2.6/5
BeOne

BeOne (ONC US)

150
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
bullishBeOne
03 Jul 2025 22:11Broker

BeiGene (ONC US) - CDK4i Showed Preliminary Efficacy While Data Still Maturing

BeOne’s CDK4 inhibitor (BGB-43395) shows a favorable hematologic safety profile, supported by improved CDK4/CDK6 selectivity that reduces off...

Logo
319 Views
Share
bullishBeiGene
14 May 2025 07:15

Quiddity Leaderboard Hang Seng Index Jun25: Beigene Is Our Top Pick

We expect the ADDs/DELs and indicative weights for the Hang Seng Index to be publicly confirmed on Friday 16th May 2025. This is a good time to...

Logo
1.2k Views
Share
bullishBeiGene
11 May 2025 01:32

China Healthcare Weekly (May11)-Trump's Executive Order, Pharmacy's Risks, BeiGene 25Q1 Result Is Ok

​Trump aims to boost US drug manufacturing by reducing regulatory barriers, leading to industry changes. VBP will accelerate pharmacy closures....

Logo
448 Views
Share
bullishBeOne
09 May 2025 13:05Broker

BeiGene (ONC US) - First-Ever Quarterly GAAP Profit Marks Major Milestone

Sales of zanubrutinib remained strong. BeiGene reported product revenue of US$1.11bn in 1Q25 (+48% YoY, -1% QoQ), with zanubrutinib (Zanu)...

Logo
248 Views
Share
06 Jul 2025 01:18

China Healthcare Weekly (Jul.6)- Anjoy’s IPO Debut, HEC CJ Pharma's Merger with Sunshine Lake Pharma

11th VBP may include big variety of Sunshine Lake Pharma/Huadong/Hansoh. Anjoy's IPO is fairly priced but shares upside is limited.HEC Pharma's...

Logo
333 Views
Share
x